The Hidden Battle in Oral GLP-1s: Why Delivery Tech May Decide the Winners $LEXX $NVO $LLY 🚨‼️💰

Something interesting is setting up in the background of the oral GLP-1 race, and it’s no longer just about who has the best molecule. It’s about who can make these drugs work orally without destroying tolerability ‼️ Injectable GLP-1s and dual agonists are already incredibly effective, but nausea, vomiting, and GI discontinuation remain a real bottleneck — especially when you move to daily oral dosing. That’s where delivery technology becomes strategic, not optional. Lexaria’s Phase 1b data meaningfully changed its position in that race. For the first time in humans, DehydraTECH-delivered semaglutide showed substantially fewer GI side effects than Rybelsus® while still achieving metabolic parity by week 16 on blood sugar and lipid markers. That’s critical: it suggests tolerability improvements didn’t come at the expense of efficacy. Even more interesting, body composition data hinted at less lean mass loss versus oral semaglutide, and patient-reported outcomes favored the DehydraTECH formulation. This moves Lexaria out of “interesting science” territory and into “clinically relevant signal.” What often gets overlooked is that the same Phase 1b study also demonstrated oral feasibility with tirzepatide — a much larger and more complex peptide. Safe, chronic oral dosing with measurable systemic exposure and improved tolerability suggests DehydraTECH is behaving like a platform, not a one-off semaglutide tweak. That’s where competitive dynamics start to matter. Novo Nordisk is tied to SNAC for its oral franchise, which creates IP and strategic constraints. Eli Lilly doesn’t have that limitation and faces a clear challenge: how to make tirzepatide oral without compromising adherence. With Phase 1b risk now largely retired and funding secured into 2026, Lexaria no longer needs to “prove survival.” Any follow-on studies can be partner-driven and optimization-focused rather than rescue-financed. That shift alone changes negotiating leverage. Whether it’s Novo defending its oral position or Lilly trying to leapfrog it, the delivery layer has become the real battleground — and that’s why Lexaria’s technology suddenly matters a lot more than it did six months ago.